The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Deutsche Bank analyst Emmanuel Papadakis downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The awards are presented annually to organizations in the Greater Philadelphia and Triangle (North Carolina) regions.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...